Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Siegfried Janz MD

Siegfried Janz MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications (143)

  • Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. (Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F) J Natl Cancer Inst 2019 Aug 12 PMID: 31406992 08/14/2019    
  • Myeloma sleeper agent in myeloid disguise. (Dhakal B, Janz S) Blood 2019 Jul 04;134(1):3-4 PMID: 31273002 SCOPUS ID: 2-s2.0-85069268458 07/06/2019    
  • Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. (Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S) Haematologica 2019 Jun 20 PMID: 31221780 06/22/2019    
  • Germline Risk Contribution to Genomic Instability in Multiple Myeloma. (Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P) Front Genet 2019;10:424 PMID: 31139207 PMCID: PMC6518313 05/30/2019    
  • Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. (Ali M, Kowkuntla S, Delloro DJ, Galambos C, Hathi D, Janz S, Shokeen M, Tripathi C, Xu H, Yuk J, Zhan F, Tomasson MH, Bates ML) Am J Physiol Regul Integr Comp Physiol 2019 May 01;316(5):R678-R686 PMID: 30892915 PMCID: PMC6589607 03/21/2019       1 Citation
  • Bragg filter bandwidth engineering in subwavelength grating metamaterial waveguides. (Cheben P, Čtyroký J, Schmid JH, Wang S, Lapointe J, Wangüemert-Pérez JG, Molina-Fernández Í, Ortega-Moñux A, Halir R, Melati D, Xu D, Janz S, Dado M) Opt Lett 2019 Feb 15;44(4):1043-1046 PMID: 30768051 02/16/2019       1 Citation
  • New wrinkle on deubiquitination in B-cell lymphoma. (Janz S) Blood 2018 12 13;132(24):2529-2530 PMID: 30545891 12/14/2018    
  • Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. (Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S) BMC Cancer 2018 Nov 21;18(1):1152 PMID: 30463534 PMCID: PMC6249818 11/23/2018       2 Citations
  • Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. (Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S) Blood Cancer J 2018 02 15;8(2):22 PMID: 29449574 PMCID: PMC5814454 02/17/2018       4 Citations
  • Chromosomal instability and acquired drug resistance in multiple myeloma. (Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, Gu C, Yang Y) Oncotarget 2017 Sep 29;8(44):78234-78244 PMID: 29100463 PMCID: PMC5652852 11/05/2017    
  • NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. (Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F) Leukemia 2017 07;31(7):1648-1650 PMID: 28400617 PMCID: PMC5508075 04/13/2017       5 Citations
  • Transgenic mouse model of IgM lymphoproliferative disease mimicking Waldenström macroglobulinemia. (Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S) Blood Cancer J 2016 11 04;6(11):e488 PMID: 27813533 PMCID: PMC5148059 11/05/2016       1 Citation
  • Mouse model of MYD88L265P-dependent DLBCL. (Janz S) Blood 2016 06 02;127(22):2660-1 PMID: 27257177 06/04/2016       1 Citation
  • PIAS1 Promotes Lymphomagenesis through MYC Upregulation. (Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP) Cell Rep 2016 06 07;15(10):2266-2278 PMID: 27239040 PMCID: PMC4899214 05/31/2016       6 Citations
  • KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. (Rosean TR, Holman CJ, Tompkins VS, Jing X, Krasowski MD, Rose-John S, Janz S) Blood Cancer J 2016 Feb 26;6:e398 PMID: 26918362 PMCID: PMC4771969 02/27/2016       8 Citations
  • FOXM1 is a therapeutic target for high-risk multiple myeloma. (Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S) Leukemia 2016 Apr;30(4):873-82 PMID: 26648534 PMCID: PMC4826574 12/10/2015       18 Citations
  • Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? (Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G) Oncotarget 2015 Dec 01;6(38):40496-506 PMID: 26415231 PMCID: PMC4747348 09/29/2015       23 Citations
  • Adoptive B-cell transfer mouse model of human myeloma. (Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S) Leukemia 2016 Apr;30(4):962-6 PMID: 26202932 PMCID: PMC4821809 07/24/2015       2 Citations
  • RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival. (Zhang L, Blackwell K, Workman LM, Chen S, Pope MR, Janz S, Habelhah H) Mol Cell Biol 2015 Oct;35(19):3324-38 PMID: 26195820 PMCID: PMC4561725 07/22/2015       10 Citations
  • CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. (Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S) Exp Hematol Oncol 2015;4:9 PMID: 25838973 PMCID: PMC4383050 04/04/2015    
  • Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604 PMID: 25589346 PMCID: PMC4384656 01/16/2015       30 Citations
  • NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. (Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE) PLoS One 2014;9(11):e112126 PMID: 25393878 PMCID: PMC4231569 11/14/2014       5 Citations
  • The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. (Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd, Waldschmidt TJ, Janz S) Leukemia 2015 Jan;29(1):233-7 PMID: 25257990 PMCID: PMC4286499 09/27/2014       13 Citations
  • NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. (Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F) Oncotarget 2014 Dec 15;5(23):11986-97 PMID: 25230277 PMCID: PMC4322982 09/18/2014       22 Citations
  • Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. (Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM, Doskey CM, Buettner GR, Goswami PC) Radiat Res 2014 Oct;182(4):420-9 PMID: 25229973 PMCID: PMC4221113 09/18/2014       7 Citations
  • Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. (Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S) Immunol Res 2014 Aug;59(1-3):188-202 PMID: 24845460 PMCID: PMC4209159 05/23/2014       19 Citations
  • A new model of LMP1-MYC interaction in B cell lymphoma. (Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA) Leuk Lymphoma 2014 Dec;55(12):2917-23 PMID: 24605938 PMCID: PMC4207734 03/13/2014       2 Citations
  • ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. (Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J, Zhan F) Leukemia 2014 May;28(5):1155-8 PMID: 24365790 PMCID: PMC4018236 12/25/2013       28 Citations
  • (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. (Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S) Blood Cancer J 2013 Nov 29;3:e165 PMID: 24292417 PMCID: PMC3880444 12/03/2013    
  • Identification of candidate B-lymphoma genes by cross-species gene expression profiling. (Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A, Jacobus L, Wang Z, Lifton S, Raychaudhuri P, Morse HC 3rd, Weiner G, Link B, Smith BJ, Janz S) PLoS One 2013;8(10):e76889 PMID: 24130802 PMCID: PMC3793908 10/17/2013       4 Citations
  • Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. (Janz S) ISRN Hematol 2013 Sep 09;2013:815325 PMID: 24106612 PMCID: PMC3782845 10/10/2013    
  • Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. (Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S) Biochem Biophys Res Commun 2013 Jul 12;436(4):660-5 PMID: 23764397 PMCID: PMC3749779 06/15/2013       17 Citations
  • Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. (Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B) Leukemia 2013 Oct;27(10):2075-7 PMID: 23728080 PMCID: PMC4053943 06/04/2013       26 Citations
  • Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. (Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG) Mol Cancer Ther 2013 Jun;12(6):1140-50 PMID: 23536725 PMCID: PMC4076840 03/29/2013       38 Citations
  • Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. (Han SS, Son DJ, Yun H, Kamberos NL, Janz S) Leuk Res 2013 Feb;37(2):146-54 PMID: 23237561 PMCID: PMC3551475 12/15/2012       29 Citations
  • The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. (Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, Rosenwald A, Bargou R, Bommert K) Leukemia 2013 Feb;27(2):441-50 PMID: 22772059 PMCID: PMC4047128 07/10/2012       15 Citations
  • Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms. (Qi CF, Kim YS, Xiang S, Abdullaev Z, Torrey TA, Janz S, Kovalchuk AL, Sun J, Chen D, Cho WC, Gu W, Morse HC 3rd) Int J Mol Sci 2012;13(5):6204-19 PMID: 22754359 PMCID: PMC3382761 07/04/2012       13 Citations
  • HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. (Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S) Blood 2012 May 31;119(22):5173-81 PMID: 22490805 PMCID: PMC3370672 04/12/2012       71 Citations
  • Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. (LeGrand J, Park ES, Wang H, Gupta S, Owens JD Jr, Nelson PJ, DuBois W, Bair T, Janz S, Mushinski JF) Blood 2012 Jan 26;119(4):1018-28 PMID: 22147894 PMCID: PMC3271714 12/08/2011       5 Citations
  • Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. (Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S) Clin Cancer Res 2011 Dec 01;17(23):7313-23 PMID: 21903769 PMCID: PMC3443972 09/10/2011       69 Citations
  • B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. (Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ) Proc Natl Acad Sci U S A 2010 Nov 02;107(44):18956-60 PMID: 20956327 PMCID: PMC2973856 10/20/2010       43 Citations
  • Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. (de Jong D, Janz S) J Pathol 2010 Jul;221(3):242-7 PMID: 20527018 PMCID: PMC3118561 06/09/2010    
  • Genetic reporter system for oncogenic Igh-Myc translocations in mice. (Takizawa M, Kim JS, Tessarollo L, McNeil N, Waldschmidt TJ, Casellas R, Ried T, Janz S) Oncogene 2010 Jul 15;29(28):4113-20 PMID: 20453890 PMCID: PMC3108853 05/11/2010       1 Citation
  • NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. (Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S) Mol Cancer 2010 Apr 30;9:97 PMID: 20433747 PMCID: PMC2876994 05/04/2010       75 Citations
  • Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. (Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM) Leukemia 2010 Jun;24(6):1171-8 PMID: 20393505 PMCID: PMC3118571 04/16/2010       12 Citations
  • IL-6 and MYC collaborate in plasma cell tumor formation in mice. (Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S) Blood 2010 Mar 04;115(9):1746-54 PMID: 20018915 PMCID: PMC2832814 12/19/2009       35 Citations
  • Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. (Schüler F, Dölken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, Rabkin CS, Dölken G) Int J Cancer 2009 Feb 15;124(4):958-63 PMID: 19030176 PMCID: PMC4216731 11/26/2008       58 Citations
  • Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. (Khuda SE, Loo WM, Janz S, Van Ness B, Erickson LD) J Immunol 2008 Dec 01;181(11):7537-49 PMID: 19017943 PMCID: PMC2841033 11/20/2008       20 Citations
  • Mechanisms and consequences of chromosomal translocation. (Rabkin CS, Janz S) Cancer Epidemiol Biomarkers Prev 2008 Aug;17(8):1849-51 PMID: 18708370 PMCID: PMC2562255 08/19/2008       1 Citation
  • t(14;18) Translocations and risk of follicular lymphoma. (Rabkin CS, Hirt C, Janz S, Dölken G) J Natl Cancer Inst Monogr 2008(39):48-51 PMID: 18648003 07/24/2008       19 Citations
  • Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. (Janz S) J Natl Cancer Inst Monogr 2008(39):37-40 PMID: 18648000 07/24/2008       5 Citations
  • Overview of mechanisms and consequences of chromosomal translocation. (Rabkin CS, Janz S) J Natl Cancer Inst Monogr 2008(39):1 PMID: 18647992 07/24/2008    
  • AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. (Kovalchuk AL, duBois W, Mushinski E, McNeil NE, Hirt C, Qi CF, Li Z, Janz S, Honjo T, Muramatsu M, Ried T, Behrens T, Potter M) J Exp Med 2007 Nov 26;204(12):2989-3001 PMID: 17998390 PMCID: PMC2118515 11/14/2007       38 Citations
  • Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. (Fujita K, Janz S) Mol Cancer 2007 Oct 30;6:71 PMID: 17971207 PMCID: PMC2173906 SCOPUS ID: 2-s2.0-37749040562 11/01/2007       119 Citations
  • Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. (Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF) BMC Genomics 2007 Aug 31;8:302 PMID: 17764563 PMCID: PMC2040348 09/04/2007       19 Citations
  • In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development. (Yan Y, Park SS, Janz S, Eckhardt LA) Genes Chromosomes Cancer 2007 Oct;46(10):950-9 PMID: 17639584 PMCID: PMC2742353 07/20/2007       14 Citations
  • Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. (Hirt C, Dölken G, Janz S, Rabkin CS) Br J Haematol 2007 Aug;138(3):349-53 PMID: 17614821 07/07/2007       30 Citations
  • A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. (Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG) Cancer Res 2007 May 01;67(9):4069-78 PMID: 17483317 05/08/2007       32 Citations
  • Regulation of AID expression in the immune response. (Crouch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gourzi P, Montaño C, Feigenbaum L, Wilson P, Janz S, Papavasiliou FN, Casellas R) J Exp Med 2007 May 14;204(5):1145-56 PMID: 17452520 PMCID: PMC2118564 04/25/2007       168 Citations
  • Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. (Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, Kovalchuk AL, Fredrickson TN, Hartley JW, Roopenian DC, Davidson WF, Janz S, Morse HC 3rd) Cancer Res 2007 Mar 15;67(6):2439-47 PMID: 17363561 03/17/2007       21 Citations
  • Myc translocations in B cell and plasma cell neoplasms. (Janz S) DNA Repair (Amst) 2006 Sep 08;5(9-10):1213-24 PMID: 16815105 07/04/2006       77 Citations
  • CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. (Han SS, Peng L, Chung ST, DuBois W, Maeng SH, Shaffer AL, Sporn MB, Janz S) Mol Cancer 2006 Jun 07;5:22 PMID: 16759389 PMCID: PMC1553469 06/09/2006       13 Citations
  • Plasma cell tumour progression in iMycEmu gene-insertion mice. (Kim JS, Han SS, Park SS, McNeil N, Janz S) J Pathol 2006 May;209(1):44-55 PMID: 16482495 02/17/2006       9 Citations
  • Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. (Han SS, Shaffer AL, Peng L, Chung ST, Lim JH, Maeng S, Kim JS, McNeil N, Ried T, Staudt LM, Janz S) Mol Cancer 2005 Nov 09;4:40 PMID: 16277667 PMCID: PMC1298327 11/10/2005       5 Citations
  • Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. (Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM, Janz S) Cancer Res 2005 Sep 01;65(17):7644-52 PMID: 16140930 09/06/2005       19 Citations
  • Uncovering MYC's full oncogenic potential in the hematopoietic system. (Janz S) Oncogene 2005 May 19;24(22):3541-3 PMID: 15782131 03/23/2005       7 Citations
  • Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. (McNeil N, Kim JS, Ried T, Janz S) Genes Chromosomes Cancer 2005 Jun;43(2):137-46 PMID: 15751044 03/08/2005       5 Citations
  • Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. (Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S) Cancer Res 2005 Feb 15;65(4):1306-15 PMID: 15735016 03/01/2005       89 Citations
  • Location of Myc, Igh, and Igk on Robertsonian fusion chromosomes is inconsequential for Myc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors prefer Igk-Myc inversions over translocations. (Silva S, Wiener F, Klein G, Janz S) Genes Chromosomes Cancer 2005 Apr;42(4):416-26 PMID: 15645495 01/13/2005       6 Citations
  • Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. (Zhu D, Qi CF, Morse HC 3rd, Janz S, Stevenson FK) Blood 2005 Mar 01;105(5):2135-7 PMID: 15522957 11/04/2004       31 Citations
  • Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. (Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S) J Clin Invest 2004 Jun;113(12):1763-73 PMID: 15199411 PMCID: PMC420503 06/17/2004       80 Citations
  • Selenium deficiency abrogates inflammation-dependent plasma cell tumors in mice. (Felix K, Gerstmeier S, Kyriakopoulos A, Howard OM, Dong HF, Eckhaus M, Behne D, Bornkamm GW, Janz S) Cancer Res 2004 Apr 15;64(8):2910-7 PMID: 15087411 04/17/2004       26 Citations
  • Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma. (Rockwood LD, Felix K, Janz S) Mutat Res 2004 Apr 14;548(1-2):117-25 PMID: 15063142 04/06/2004       20 Citations
  • Moderate hypermutability of a transgenic lacZ reporter gene in Myc-dependent inflammation-induced plasma cell tumors in mice. (Felix K, Polack A, Pretsch W, Jackson SH, Feigenbaum L, Bornkamm GW, Janz S) Cancer Res 2004 Jan 15;64(2):530-7 PMID: 14744766 01/28/2004       4 Citations
  • BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. (Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S) Cancer Res 2003 Dec 15;63(24):8656-63 PMID: 14695177 12/26/2003       25 Citations
  • COMBO-FISH: specific labeling of nondenatured chromatin targets by computer-selected DNA oligonucleotide probe combinations. (Hausmann M, Winkler R, Hildenbrand G, Finsterle J, Weisel A, Rapp A, Schmitt E, Janz S, Cremer C) Biotechniques 2003 Sep;35(3):564-70, 572-7 PMID: 14513562 09/30/2003       42 Citations
  • Paradoxical decrease in mutant frequencies and chromosomal rearrangements in a transgenic lacZ reporter gene in Ku80 null mice deficient in DNA double strand break repair. (Rockwood LD, Nussenzweig A, Janz S) Mutat Res 2003 Aug 28;529(1-2):51-8 PMID: 12943919 08/29/2003       14 Citations
  • E mu/S mu transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells. (Kovalchuk AL, Kim JS, Janz S) Oncogene 2003 May 08;22(18):2842-50 PMID: 12743607 05/14/2003       7 Citations
  • Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. (Janz S, Potter M, Rabkin CS) Genes Chromosomes Cancer 2003 Mar;36(3):211-23 PMID: 12557221 01/31/2003       121 Citations
  • Redox imbalance and mutagenesis in spleens of mice harboring a hypomorphic allele of Gpdx(a) encoding glucose 6-phosphate dehydrogenase. (Felix K, Rockwood LD, Pretsch W, Bornkamm GW, Janz S) Free Radic Biol Med 2003 Jan 15;34(2):226-32 PMID: 12521604 01/11/2003       8 Citations
  • Bcl-2 reduces mutant rates in a transgenic lacZ reporter gene in mouse pre-B lymphocytes. (Felix K, Rolink A, Melchers F, Janz S) Mutat Res 2003 Jan 28;522(1-2):135-44 PMID: 12517419 01/09/2003       3 Citations
  • Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. (Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse HC 3rd, Janz S) Oncogene 2002 Oct 17;21(47):7235-40 PMID: 12370814 10/09/2002       24 Citations
  • Isotype switch-mediated CH deletions are a recurrent feature of Myc/CH translocations in peritoneal plasmacytomas in mice. (Kovalchuk AL, Janz S) Int J Cancer 2002 Oct 10;101(5):423-6 PMID: 12216069 09/07/2002       5 Citations
  • Transgenic shuttle vector assays for determining genetic differences in oxidative B cell mutagenesis in vivo. (Felix K, Rockwood LD, Janz S) Methods Enzymol 2002;353:434-48 PMID: 12078516 06/25/2002       3 Citations
  • Moderate G6PD deficiency increases mutation rates in the brain of mice. (Felix K, Rockwood LD, Pretsch W, Nair J, Bartsch H, Bornkamm GW, Janz S) Free Radic Biol Med 2002 Apr 01;32(7):663-73 PMID: 11909700 03/23/2002       20 Citations
  • IL-6 transgenic mouse model for extraosseous plasmacytoma. (Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse HC 3rd, Kishimoto T, Potter M, Janz S) Proc Natl Acad Sci U S A 2002 Feb 05;99(3):1509-14 PMID: 11805288 PMCID: PMC122221 01/24/2002       103 Citations
  • Conformational differences in the 3-D nanostructure of the immunoglobulin heavy-chain locus, a hotspot of chromosomal translocations in B lymphocytes. (Esa A, Coleman AE, Edelmann P, Silva S, Cremer CG, Janz S) Cancer Genet Cytogenet 2001 Jun;127(2):168-73 PMID: 11425458 06/27/2001       21 Citations
  • Non-Hodgkin lymphomas of mice. (Hori M, Xiang S, Qi CF, Chattopadhyay SK, Fredrickson TN, Hartley JW, Kovalchuk AL, Bornkamm GW, Janz S, Copeland NG, Jenkins NA, Ward JM, Morse HC 3rd) Blood Cells Mol Dis 2001 Jan-Feb;27(1):217-22 PMID: 11358382 05/19/2001       10 Citations
  • Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. (Kovalchuk AL, Esa A, Coleman AE, Park SS, Ried T, Cremer CC, Janz S) Genes Chromosomes Cancer 2001 Mar;30(3):283-91 PMID: 11170286 02/15/2001       10 Citations
  • Inducible mutagenesis in TEPC 2372, a mouse plasmacytoma cell line that harbors the transgenic shuttle vector lambdaLIZ. (Felix K, Kovalchuk AL, Park SS, Coleman AE, Ramsay ES, Qian M, Kelliher KA, Jones GM, Ried T, Bornkamm GW, Janz S) Mutat Res 2001 Jan 25;473(1):121-36 PMID: 11166031 02/13/2001       1 Citation
  • Burkitt lymphoma in the mouse. (Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd) J Exp Med 2000 Oct 16;192(8):1183-90 PMID: 11034608 PMCID: PMC2195876 10/18/2000       151 Citations
  • Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. (Coleman AE, Ried T, Janz S) Genes Chromosomes Cancer 2000 Sep;29(1):70-4 PMID: 10918396 08/05/2000       11 Citations
  • Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. (Kovalchuk AL, Kishimoto T, Janz S) Leukemia 2000 Jun;14(6):1127-35 PMID: 10865979 06/24/2000       19 Citations
  • Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. (Kovalchuk AL, Mushinski EB, Janz S) Leukemia 2000 May;14(5):909-21 PMID: 10803525 05/10/2000       17 Citations
  • Cytogenetic analysis of the bipotential murine pre-B cell lymphoma, P388, and its derivative macrophage-like tumor, P388D1, using SKY and CGH. (Coleman AE, Forest ST, McNeil N, Kovalchuk AL, Ried T, Janz S) Leukemia 1999 Oct;13(10):1592-600 PMID: 10516761 10/12/1999       14 Citations
  • Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice. (Felix K, Kelliher KA, Bornkamm GW, Janz S) Cancer Res 1999 Aug 01;59(15):3621-6 PMID: 10446972 08/14/1999       9 Citations
  • Transgenic shuttle vector assays for assessing oxidative B-cell mutagenesis in vivo. (Felix K, Kelliher K, Bornkamm GW, Janz S) Curr Top Microbiol Immunol 1999;246:369-75; discussion 376-7 PMID: 10396077 07/09/1999    
  • Recurrent non-reciprocal translocations of chromosome 5 in primary T(12;15)-positive BALB/c plasmacytomas. (Coleman AE, Ried T, Janz S) Curr Top Microbiol Immunol 1999;246:175-80; discussion 181 PMID: 10396054 07/09/1999       4 Citations
  • Jumping translocation breakpoint regions lead to amplification of rearranged Myc. (Coleman AE, Kovalchuk AL, Janz S, Palini A, Ried T) Blood 1999 Jun 15;93(12):4442-4 PMID: 10391697 07/03/1999       11 Citations
  • Association of elevated mutagenesis in the spleen with genetic susceptibility to induced plasmacytoma development in mice. (Felix K, Kelliher K, Bornkamm GW, Janz S) Cancer Res 1998 Apr 15;58(8):1616-9 PMID: 9563470 05/01/1998       3 Citations
  • Tetravinyl-tetramethylcyclo-tetrasiloxane (tetravinyl D4) is a mutagen in Rat2lambda lacI fibroblasts. (Felix K, Lin S, Bornkamm GW, Janz S) Carcinogenesis 1998 Feb;19(2):315-20 PMID: 9498283 03/14/1998       5 Citations
  • Deletional remodeling of c-myc-deregulating chromosomal translocations. (Kovalchuk AL, Müller JR, Janz S) Oncogene 1997 Nov 06;15(19):2369-77 PMID: 9393881 12/11/1997       43 Citations
  • Elevated mutant frequencies in gene lacI in splenic lipopolysaccharide blasts after exposure to activated phagocytes in vitro. (Felix K, Lin S, Janz S) Eur J Immunol 1997 Sep;27(9):2160-4 PMID: 9341754 10/28/1997       5 Citations
  • Previously hidden chromosome aberrations in T(12;15)-positive BALB/c plasmacytomas uncovered by multicolor spectral karyotyping. (Coleman AE, Schröck E, Weaver Z, du Manoir S, Yang F, Ferguson-Smith MA, Ried T, Janz S) Cancer Res 1997 Oct 15;57(20):4585-92 PMID: 9377573 10/23/1997       38 Citations
  • Monoclonal origin of multicentric Kaposi's sarcoma lesions. (Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, Biggar RJ, Zhuang Z) N Engl J Med 1997 Apr 03;336(14):988-93 PMID: 9077377 04/03/1997       194 Citations
  • In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane). (Felix K, Potter M, Bornkamm GW, Janz S) Cancer Lett 1997 Feb 26;113(1-2):71-6 PMID: 9065804 02/26/1997       3 Citations
  • Generation of immunoglobulin/c-myc recombinations in murine Peyer's patch follicles. (Müller JR, Mushinski EB, Jones GM, Williams JA, Janz S, Hausner PF, Potter M) Curr Top Microbiol Immunol 1997;224:251-5 PMID: 9308248 01/01/1997       4 Citations
  • Genetic recombinations between c-myc and Igh mu as precursors for recombinations between c-myc and Igh alpha in BALB/c plasmacytomas. (Janz S, Kovalchuk AL, Müller JR, Potter M) Curr Top Microbiol Immunol 1997;224:241-50 PMID: 9308247 01/01/1997       2 Citations
  • Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice. (Müller JR, Jones GM, Janz S, Potter M) Blood 1997 Jan 01;89(1):291-6 PMID: 8978304 01/01/1997       28 Citations
  • Multicolour spectral karyotyping of mouse chromosomes. (Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schröck E, Ried T) Nat Genet 1996 Nov;14(3):312-5 PMID: 8896561 11/01/1996       236 Citations
  • Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. (Müller JR, Jones GM, Potter M, Janz S) Cancer Res 1996 Jan 15;56(2):419-23 PMID: 8542601 01/15/1996       25 Citations
  • DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. (Kovalchuk AL, Potter M, Janz S) Immunogenetics 1996;44(2):151-6 PMID: 8662079 01/01/1996       6 Citations
  • Completion of the DNA sequence determination of the Igh2 locus of the mouse: the 5'-IA region. (Janz S, Roschke VV) Immunogenetics 1996;43(1-2):101-4 PMID: 8537111 01/01/1996       1 Citation
  • Cytotoxicity and membrane damage in vitro by inclusion complexes between gamma-cyclodextrin and siloxanes. (Felix K, Janz S, Pitha J, Williams JA, Mushinski EB, Bornkamm GW, Potter M) Curr Top Microbiol Immunol 1996;210:93-9 PMID: 8565593 01/01/1996       6 Citations
  • Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. (Müller JR, Janz S, Potter M) Cancer Res 1995 Nov 01;55(21):5012-8 PMID: 7585544 11/01/1995       30 Citations
  • Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. (Müller JR, Janz S, Goedert JJ, Potter M, Rabkin CS) Proc Natl Acad Sci U S A 1995 Jul 03;92(14):6577-81 PMID: 7604036 PMCID: PMC41561 07/03/1995       63 Citations
  • Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice. (Janz S, Shacter E) Cancer Biochem Biophys 1995 Jun;15(1):25-34 PMID: 8536217 06/01/1995       4 Citations
  • Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane. (Janz S, Gawrisch K, Lester DS) Cancer Res 1995 Feb 01;55(3):518-24 PMID: 7834620 02/01/1995       10 Citations
  • Illegitimate recombinations between c-myc and immunoglobulin loci are remodeled by deletions in mouse plasmacytomas but not in Burkitt's lymphomas. (Müller JR, Janz S, Potter M) Curr Top Microbiol Immunol 1995;194:425-9 PMID: 7895518 01/01/1995       1 Citation
  • Genomic instability in B-cells and diversity of recombinations that activate c-myc. (Janz S, Jones GM, Müller JR, Potter M) Curr Top Microbiol Immunol 1995;194:373-80 PMID: 7895512 01/01/1995       5 Citations
  • Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. (Müller JR, Potter M, Janz S) Proc Natl Acad Sci U S A 1994 Dec 06;91(25):12066-70 PMID: 7991585 PMCID: PMC45377 12/06/1994       34 Citations
  • In vitro cytotoxicity of neutrophil-like human HL-60 cells undergoing an oxidative burst with Escherichia coli reporter strains. (Müller J, Janz S) Toxicol In Vitro 1994 Jun;8(3):437-40 PMID: 20692935 06/01/1994    
  • Fusion between enveloped viruses and erythrocyte membranes is induced by the isoprenoid alkane pristane (2,6,10,14-tetramethylpentadecane). (Janz S, Shacter E, Herrmann A) Cancer Biochem Biophys 1994 Apr;14(1):1-14 PMID: 7796384 04/01/1994       3 Citations
  • Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. (Janz S, Müller J, Shaughnessy J, Potter M) Proc Natl Acad Sci U S A 1993 Aug 01;90(15):7361-5 PMID: 8346257 PMCID: PMC47137 08/01/1993       55 Citations
  • Genotoxicity assessment of waste products of aluminum plasma etching with the SOS chromotest. (Raabe F, Janz S, Wolff G, Merten H, Landrock A, Birkenfeld T, Herzschuh R) Mutat Res 1993 Jul;300(2):99-109 PMID: 7685499 07/01/1993       6 Citations
  • Modulation of the H2O2-induced SOS response in Escherichia coli PQ300 by amino acids, metal chelators, antioxidants, and scavengers of reactive oxygen species. (Müller J, Janz S) Environ Mol Mutagen 1993;22(3):157-63 PMID: 8404875 01/01/1993       22 Citations
  • Activated murine neutrophils induce unscheduled DNA synthesis in B lymphocytes. (Janz S, Shacter E) Mutat Res 1993 Jan;293(2):173-86 PMID: 7678145 01/01/1993       12 Citations
  • The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis. (Janz S, Krumbiegel M, Gawrisch K) Cancer Biochem Biophys 1992 Nov;13(2):85-92 PMID: 1343851 11/01/1992       3 Citations
  • Assessment of oxidative DNA damage in the oxyR-deficient SOS chromotest strain Escherichia coli PQ300. (Müller J, Janz S) Environ Mol Mutagen 1992;20(4):297-306 PMID: 1425609 01/01/1992       15 Citations
  • The uptake of pristane (2,6,10,14-tetramethylpentadecane) into phospholipid bilayers as assessed by NMR, DSC, and tritium labeling methods. (Gawrisch K, Janz S) Biochim Biophys Acta 1991 Dec 09;1070(2):409-18 PMID: 1764453 12/09/1991       9 Citations
  • The reaction of pristane (2,6,10,14-tetramethylpentadecane) with radiolytically generated reactive oxygen intermediates results in a stable genotoxic compound as assessed by the SOS chromotest. (Janz S, Brede O, Müller J) Carcinogenesis 1991 Jul;12(7):1241-6 PMID: 2070489 07/01/1991       2 Citations
  • A new method for delivering alkanes to mammalian cells: preparation and preliminary characterization of an inclusion complex between beta-cyclodextrin and pristane (2,6,10,14-tetramethylpentadecane). (Janz S, Shacter E) Toxicology 1991;69(3):301-15 PMID: 1949053 01/01/1991       20 Citations
  • DNA damage induced by phorbol ester-stimulated neutrophils is augmented by extracellular cofactors. Role of histidine and metals. (Shacter E, Lopez RL, Beecham EJ, Janz S) J Biol Chem 1990 Apr 25;265(12):6693-9 PMID: 2157707 04/25/1990       49 Citations
  • Application of an alternative approach for using the SOS chromotest to screen complex indeterminate mixtures. (Janz S, Raabe F, Wolff G) Zentralbl Mikrobiol 1990;145(3):177-82 PMID: 2196748 01/01/1990       7 Citations
  • The effect of non-ionic surfactants on the SOS-inducing potency of 4-nitroquinoline-1-oxide in Escherichia coli PQ37. (Raabe F, Janz S, Wolff G) J Basic Microbiol 1990;30(6):435-42 PMID: 2126282 01/01/1990       4 Citations
  • [Histologic studies of paraproteinemic nephropathy in BALB/c mice with mineral oil-induced plasmacytoma]. (Janz S, Rassmann B, Raabe F, Storch H) Z Urol Nephrol 1989 Dec;82(12):671-8 PMID: 2629422 12/01/1989    
  • Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice. (Janz S, Birkenfeld T, Herzschuh R, Storch H) Arch Geschwulstforsch 1989;59(6):415-22 PMID: 2596957 01/01/1989       3 Citations
  • [Experimental research on the genotoxicity of various root canal antiseptics in the SOS chromotest]. (Klimm W, Janz S, Gabert A) Zahn Mund Kieferheilkd Zentralbl 1989;77(2):128-30 PMID: 2526434 01/01/1989       7 Citations
  • Quantitation of the relationship between tester cell number inoculated and SOS-inducing potency of 4-nitroquinoline-1-oxide (4-NQO) in an automated version of the SOS chromotest. (Janz S, Wolff G, Huttunen T, Raabe F, Storch H) J Basic Microbiol 1989;29(7):403-11 PMID: 2513384 01/01/1989       14 Citations
  • Genotoxicity assessment of the plasmacytomagenic agent pristane (2.6.10.14-tetramethylpentadecane) and four related alkanes by the SOS chromotest. (Janz S, Huttunen T, Herzschuh R, Storch H) Arch Geschwulstforsch 1988;58(2):73-8 PMID: 3288166 01/01/1988       2 Citations
  • SOS chromotest, a quantitative short-term bacterial assay for the detection of genotoxic compounds in an automated version adapted to Bioscreen Analyzer System. (Janz S, Wolff G, Storch H) Zentralbl Mikrobiol 1988;143(8):645-9 PMID: 3149098 01/01/1988       14 Citations
  • Evidence for high purity of a commercial pristane (2,6,10,14-tetramethylpentadecane) preparation used for plasmocytoma induction in BALB/c mice. (Janz S, Herzschuh R, Storch H) Exp Pathol 1987;31(4):253-5 PMID: 3622726 01/01/1987       1 Citation
  • Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA). (Janz S, Püschel W, Raabe F, Storch H) Arch Geschwulstforsch 1987;57(1):25-30 PMID: 3566462 01/01/1987    
  • Last update: 10/06/2019
    jenkins-FCD Prod-387 b0ced2662056320369de4e5cd5f21c218c03feb3